Phase 1 Study of HS-10541 as Monotherapy or in Combination With Other Anti-cancer Therapies in Patients With KRAS G12C Mutation Advanced Solid Tumors.

Exclusion Criteria

• •1. Uncontrolled pleural effusion, pericardial effusion, or abdominal effusion requiring clinical intervention.
• •2. Presence of symptomatic brain metastases, leptomeningeal/brainstem involvement, history of intracranial hemorrhage or intraspinal hemorrhage, or spinal cord compression.
• •3. Unresolved CTCAE ≥grade 2 toxicities from previous anticancer therapy.
• •4. History of a second primary malignancy
• •5. Severe, uncontrolled, or active cardiovascular or cerebrovascular diseases, or severe cardiac examination abnormalities.
• •6. Severe or poorly controlled diabetes mellitus or hypertension.
• •7. Known active infectious diseases.
• •8. Clinically significant gastrointestinal dysfunction.
• •9. Gastrointestinal obstruction or perforation occured.
• •10. Interstitial lung disease (ILD).
• •11. Participants with known hypersensitivity or contraindications to any active or inactive ingredients of the study drug, chemically similar drugs, or drugs of the same class.
• •12. Other inappropriate situation considered by the investigator.